London · Delayed Price · Currency is GBP · Price in SEK Medivir AB Statistics
Total Valuation
Medivir AB has a market cap or net worth of GBP 17.15 million. The enterprise value is 14.70 million.
| Market Cap | 17.15M |
| Enterprise Value | 14.70M |
Important Dates
The last earnings date was Thursday, August 21, 2025.
| Earnings Date | Aug 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 112.17M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +28.57% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 84.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 56.07 |
| PB Ratio | 2.81 |
| P/TBV Ratio | 2.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.96 |
| EV / Sales | 46.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.70, with a Debt / Equity ratio of 0.09.
| Current Ratio | 0.70 |
| Quick Ratio | 0.70 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.32 |
Financial Efficiency
Return on equity (ROE) is -76.62% and return on invested capital (ROIC) is -45.48%.
| Return on Equity (ROE) | -76.62% |
| Return on Assets (ROA) | -32.17% |
| Return on Invested Capital (ROIC) | -45.48% |
| Return on Capital Employed (ROCE) | -114.22% |
| Revenue Per Employee | 30,580 |
| Profits Per Employee | -751,571 |
| Employee Count | 10 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.38% in the last 52 weeks. The beta is 0.33, so Medivir AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -33.38% |
| 50-Day Moving Average | 4.37 |
| 200-Day Moving Average | 23.72 |
| Relative Strength Index (RSI) | 32.94 |
| Average Volume (20 Days) | 6,879 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medivir AB had revenue of GBP 305,795 and -7.52 million in losses. Loss per share was -0.07.
| Revenue | 305,795 |
| Gross Profit | -5.33M |
| Operating Income | -7.63M |
| Pretax Income | -7.52M |
| Net Income | -7.52M |
| EBITDA | -7.62M |
| EBIT | -7.63M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 2.93 million in cash and 567,993 in debt, giving a net cash position of 2.36 million.
| Cash & Cash Equivalents | 2.93M |
| Total Debt | 567,993 |
| Net Cash | 2.36M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.11M |
| Book Value Per Share | 0.05 |
| Working Capital | -1.36M |
Cash Flow
| Operating Cash Flow | -8.90M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,494.23% |
| Pretax Margin | -2,457.76% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Medivir AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.57% |
| Shareholder Yield | -28.57% |
| Earnings Yield | -43.84% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medivir AB has an Altman Z-Score of -8.49. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.49 |
| Piotroski F-Score | n/a |